Company News

Share this article:

Wyeth and Catalyst Biosciences announced a worldwide collaboration for the discovery, development and commercialization of Factor Vlla products to treat hemophilia and other bleeding conditions. The deal included an upfront payment of $21 million, and total payments “could exceed $500 million,” according to the statement. Wyeth will be responsible for the manufacturing and commercialization of products resulting from the collaboration, including CB 813, an investigational candidate for the treatment of acute bleeding in patients with hemophilia.

A jury awarded J&J's Centocor Ortho Biotech $1.67 billion in a patent infringement suit against Abbott Laboratories. The patent in question was an anti-TNF class of arthritis treatments, co-owned by New York University and Centocor, according to the release. Abbott's drug Humira (adalimumab), which had sales in the billions last year, was found to infringe.

Keltman Pharmaceuticals has contracted inVentiv Selling Solutions to provide a sales team that will supplement the Flowood, MS-based wholesale pharma firm's in-house  team, maintaining in-office medicine dispensing systems for physicians.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.